Stockwinners Market Radar for October 19, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EDT Everspin Technologies signs contract with QuickLogic to provide MRAM IP - Everspin Technologies (MRAM) has signed a contract to provide MRAM technology, design, and back end of line manufacturing services with QuickLogic (QUIK). The initial award is potentially valued at $2.8M, with subsequent options bringing the total to approximately $8.7M. This is part of an award to develop and demonstrate Strategic Radiation Hardened, high reliability Field Programmable Gate Array technology to support identified and future Department of Defense strategic and space system requirements. This project is sponsored by DoD's Trusted and Assured Microelectronics Program.

19:53 EDT Alarm.com acquires Noonlight, terms not stated - Alarm.com "announced it completed a majority-stake acquisition of Noonlight, a next-generation connected safety and event management platform that enables new applications and provides enhanced emergency response capabilities. Noonlight will continue to operate independently as a next generation IoT device monitoring provider, as well as a consumer safety app and brand that millions of users trust. Noonlight's current management team will continue to lead the business from its headquarters in St. Louis, Mo."

18:47 EDT Philip Morris acquires U.S. commercialization rights to IQOS from Altria - Altria Group (MO) announced that a subsidiary has entered into an agreement with a subsidiary of Philip Morris International Inc. (PM) under which Altria will receive cash payments from PMI totaling approximately $2.7B in exchange for assigning exclusive U.S. commercialization rights to the IQOS Tobacco Heating System effective April 30, 2024. "We remain committed to creating long-term value through our Vision," said Billy Gifford, Altria's Chief Executive Officer. "We believe that this agreement provides us with fair compensation and greater flexibility to allocate resources toward Moving Beyond Smoking." "We received a payment from PMI of $1.0 billion upon entry into the Agreement," Altria said. "Under the terms of the Agreement, PMI is obligated to make an additional payment of $1.7 billion (plus interest) by July 2023 for a total cash payment of approximately $2.7 billion (pre-tax). We expect to use the cash proceeds for several items, which may include investments in pursuit of our Vision, debt repayment, share repurchases and general corporate purposes. Share repurchases depend on marketplace conditions and other factors and remain subject to the discretion of our Board of Directors. We expect to record the $2.7 billion pre-tax transaction amount as a deferred gain on our consolidated balance sheet in the fourth quarter of 2022. This gain will be recognized in earnings when we assign our rights to the IQOS system."

17:52 EDT Tesla says on track for 50% annual growth production this year - CFO Zachary Kirkhorn says: "As we look ahead, our plans show that we're on track for the 50% annual growth in production this year, although we are tracking supply chain risks which are beyond our control. On the delivery side, we do expect to be just under 50% growth due to an increase in the cars in transit at the end of the year."

17:41 EDT Tesla CEO says factories running at full speed, long-term trend 'extremely good' - Says intend to keep raising production in Fremont. Says it's likely we will do some "meaningful buyback", possible for Tesla to do buyback of $5B-$10B, pending board approval. Comments taken from Q3 earnings conference call.

17:35 EDT Fidelity D & D Bancorp raises quarterly dividend 9% to 36c from 33c per share - Payable December 9 to shareholders of record at the close of business on November 18.

17:28 EDT Allstate drops 8% to $124.00 after Q3 guidance

17:20 EDT HP Enterprise sees revenue growth up 2%-4% over the long term - HPE "provided its long-term financial model for FY22 through FY25. The company expects its unique HPE GreenLake edge-to-cloud platform will drive robust growth. HPE projects revenue growth of 2% to 4% adjusted for currency, led by healthy growth in Aruba and High Performance Computing & AI, and a compounded annual growth rate for annualized revenue run-rate of 35% to 45%. Additionally, it expects greater than $6.5 billion of cumulative free cash flow between fiscal year 2022 and fiscal year 2024, powered by sustained revenue growth, rising operating profits, and underpinned by strategic investments."

17:11 EDT Celanese raises quarterly cash dividend to 70c from 68c per share - Payable on November 14 to stockholders of record as of October 31.

17:01 EDT ZK International receives Nasdaq notice regarding minimum bid requirements - ZK International Group announced that the company received a notice from the Nasdaq Stock Market LLC, dated Oct. 13, 2022, notifying the company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1) because the bid price of the company's ordinary shares fail to maintain a minimum bid price of $1.00 per share for the last 30 consecutive business days from August 31, 2022 to October 12, 2022.

16:46 EDT Black Stone Minerals raises dividend 7% to 45c per unit - Distributions will be payable on November 17, 2022 to unitholders of record on November 10, 2022.

16:40 EDT Alcoa falls 8.3% to $34.50 afterhours following Q3 earnings miss

16:38 EDT Ranger Oil says volumes were approximately 42.6 Mboe/d - Ranger Oil sees Q3 total sales volumes ~42.6 thousand barrels of Oil equivalent per day, exceeding top end ff guidance range Of 40.9 - 42.5 thousand barrels of Oil equivalent per day. Realized oil prices were approximately $93.03 per barrel, a premium to the quarterly WTI benchmark, or $83.14 per barrel including effects of derivatives, net1. Drilling and completion capital expenditures were approximately $151.9M, which included approximately $3.4M of incremental capital due to D&C operations completed ahead of schedule. D&C capital in the quarter was in-line with the Company's guidance range of $135 - $160M. Ranger continues to find innovative ways to offset industry-wide inflationary pressures and ensure wells get turned to sales on time and on budget.

16:35 EDT OFS Credit estimates NAV per share of $9.94-$10.04 as of September 30, 2022 - OFS Credit Company announced the following net asset value estimate as of September 30, 2022. Management's unaudited estimate of the range of our NAV per share of our common stock as of September 30, 2022 is between $9.94 and $10.04. This estimate is not a comprehensive statement of the company's financial condition or results for the month ended September 30, 2022. This estimate did not undergo the company's typical quarter-end financial closing procedures.

16:34 EDT Bristol-Myers reports Opdivo data in resected stage IIB or IIC melanoma - Bristol Myers "announced results from the Phase 3 CheckMate -76K trial, in which Opdivo as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo in patients with completely resected stage IIB or IIC melanoma. At a pre-specified interim analysis, the trial met its primary endpoint of recurrence-free survival; Opdivo reduced the risk of recurrence or death by 58% versus placebo. Twelve-month RFS rates for Opdivo were 89% versus 79% for placebo. The RFS benefit was observed across predefined subgroups in the trial, including T category and disease stage. These results are being presented as late-breaking data at the 2022 Society for Melanoma Research Annual Meeting taking place October 17-20, 2022, during a plenary session on October 19 in Edinburgh, Scotland. The safety profile of Opdivo was consistent with that seen in previously reported studies and no new safety signals were observed at the time of the analysis. Grade 3/4 treatment-related adverse events were 10% in the Opdivo arm and 2% in the placebo arm. TRAE-related discontinuation was 15% for those in the Opdivo arm and 3% for those in the placebo arm. "

16:33 EDT Steel Dynamics says 'customer order entry activity continues to be healthy' - "Customer order entry activity continues to be healthy across our businesses, with expectations for seasonally moderated volume for our steel and metals recycling operations in the coming months," saidCEO Millett. "Despite weaker flat rolled steel pricing, our order activity and backlogs remain solid. We believe North American steel consumption will remain steady, and that demand for lower-carbon, U.S. produced steel products coupled with lower imports will support steel pricing. Our steel fabrication operations order backlog also remains historically high based on volume and forward pricing levels. This, in combination with our existing and recently announced expansion initiatives, are firm drivers for our continued growth in the coming years. Operations continue to ramp up at our Sinton Flat Roll Steel Division. The product surface quality is excellent, and grade development and dimensional tolerances have exceeded our expectations. The Sinton team has been running at a rate of 65 percent during October and achieving rates of over 80 percent for several single day periods, supporting our expectations to achieve a run rate of at least 80 percent for the full year 2023. In addition, our four additional value-added flat rolled steel coating lines comprised of two paint lines and two galvanizing lines with Galvalume(R) coating capability, are expected to begin operating in the second half of 2023. One set will be located onsite at Sinton, providing it with the same diversification and higher-margin product capabilities as our two existing flat rolled steel divisions. The other two lines will be placed at our Heartland Flat Roll Division to support growing coated flat rolled steel demand in the region and to further increase the diversification and cash generation capacity of our existing Midwest operations. We are quickly progressing on our aluminum flat rolled products mill and are incredibly excited about this meaningful growth opportunity, which is aligned with our existing business and operational expertise," said Millett. "We have intentionally grown with our customers' needs, providing efficient sustainable supply-chain solutions for the highest quality products. Thus far, this has primarily been achieved within the carbon steel industry - however, a significant number of our carbon flat rolled steel customers are also consumers and processors of aluminum flat rolled products. We are pleased to further diversify our end markets with plans to supply aluminum flat rolled products with high recycled content to the countercyclical sustainable beverage can industry, in addition to the automotive and industrial sectors. We believe our unique performance-based operating culture, coupled with our considerable experience in successfully constructing and operating cost-effective, highly profitable flat rolled steel mills, positions us exceptionally well to execute this strategic opportunity and to deliver strong long-term value creation. Our customers and our people are also incredibly excited for this growth opportunity. Our commitment is to the health and safety of our teams, families, and communities, while meeting the growing needs of our customers. Our culture and business model continue to positively differentiate our performance compared to others. We believe there are strong drivers for our continued growth, and we remain in a position of strength. Our planned investments in a new state-of-the-art low-carbon aluminum flat rolled mill and associated recycled aluminum slab centers continues our strategic growth, is aligned with our core steelmaking and recycling platforms, benefits many of our existing customers, and provides for future value creation. We are well-positioned for sustainable long-term growth," concluded Millett.

16:26 EDT Crown Castle increases quarterly dividend 6.5% to $1.57 per share - Crown Castle's board declared a quarterly cash dividend of $1.57 per common share, representing an increase of approximately 6.5% over the previous quarterly dividend of $1.47 per share. The quarterly dividend will be payable on December 30 to common stockholders of record at the close of business on December 15.

16:20 EDT Alcoa backs 2022 total Aluminum segment shipments view of 2.5-2.6M Mt - Alcoa "expects total Aluminum segment shipments to remain unchanged from the prior projection, ranging between 2.5 and 2.6 million metric tons in 2022. In Alumina, the Company has decreased its 2022 projection for shipments to range between 13.1 and 13.3 million metric tons, a reduction of 0.5 million metric tons from the prior projection primarily due to the reduced production at the San Ciprian refinery and lower shipments from the Australian refineries. In Bauxite, the Company has decreased its 2022 projection for annual bauxite shipments to range between 43.0 and 44.0 million dry metric tons, a decrease of 1 million dry metric tons from the prior projection due to lower demand from the Australian refineries. For the fourth quarter of 2022, Alcoa expects higher sequential profitability in the Bauxite segment with increased third-party shipments. In Alumina, the Company anticipates lower energy costs for the San Ciprian refinery during the fourth quarter. Additionally, benefits of the San Ciprian curtailment are expected to offset the impact of lower bauxite quality in Australia and higher raw materials costs. In the Aluminum segment, higher raw materials costs, lower Warrick power plant sales, and lower value add product premiums are expected to be offset by lower energy costs at the Lista smelter."

16:17 EDT Everest Re estimates pre-tax net catastrophe losses of $730M for Q3 - Everest Re Group announced preliminary third quarter 2022 catastrophe losses in advance of its full quarterly earnings to be released on October 26, 2022. Everest is estimating total pre-tax net catastrophe losses of $730M for the third quarter 2022. All amounts are net of estimated recoveries and reinstatement premiums. For Hurricane Ian, Everest's loss estimate is based on insured industry losses of approximately $55B, driven in part by the significant social inflation in Florida. For all other global catastrophe events, Everest's loss estimate is based on insured industry losses of approximately $15B. "Our thoughts are with those impacted by the severe weather events across the globe. We are dedicated to supporting our customers in their time of need," said Juan C. Andrade, President and CEO of Everest Re Group. "Hurricane Ian is likely to be the second largest hurricane driven industry loss in U.S. history. Everest's focused execution of its diversification strategy combined with our underwriting discipline, has mitigated our total exposure to approximately 1% of our currently estimated Hurricane Ian industry loss with our reinsurance division expected to be less than 1%."

16:15 EDT Tesla down 5% in after-hours following Q3 report - Tesla shares are down $10.34, or 5%, to $211.70 in after-hours trading.

16:14 EDT Tesla says initial phase of Semi deliveries scheduled to begin in December - Tesla said in its quarterly letter: "The pace of production ramps in Texas and Berlin-Brandenburg will be influenced by the successful introduction of many new product and manufacturing technologies in new locations and ongoing supply chain related challenges... We are making progress on the industrialization of Cybertruck, which is currently planned for Texas production subsequent to Model Y ramp. The initial phase of Tesla Semi deliveries is scheduled to begin in December 2022."

16:11 EDT IBM reports Q3 cash from operating activities $6.5B - Reports Q3 free cash flow $4.1B. "Both our revenue growth and operating profit profile for the first three quarters of the year align to the investment thesis we outlined last fall," said James Kavanaugh, IBM senior vice president and chief financial officer. "Our portfolio mix, business fundamentals, strong recurring revenue stream and solid cash generation allow us to invest for continued growth and return value to shareholders through dividends."

16:11 EDT LMP Automotive announces asset sale deals with Morgan Auto Group - LMP Automotive Holdings announced it has entered into definitive dealership and real estate asset sale agreements to sell LMP's Kia dealerships in Port Charlotte, FL and Cape Coral, FL to Morgan Auto Group. Morgan Auto Group owns and operates fifty-eight franchise dealerships throughout the state of Florida. They acquired their first Kia dealership in 2015 and own and operate five Kia dealerships in the state of Florida today. There are no financing contingencies associated with these acquisitions and the funds are readily available internally at Morgan Auto Group to close. The Company anticipates that the expected closing of the Sale will occur prior to year-end, subject to the terms of the Agreements and numerous conditions precedent to Closing including but not limited to regulatory approval including any approval necessary under the Hart-Scott Rodino Antitrust Act.Furthermore, LMP expects to close on its Tennessee dealership and real-estate interest sale in the coming weeks. Additionally, LMP has received Indications of Interest for its Beckley, WV, its Subaru and Kia dealerships in Beckley, WW, its Chevrolet dealership in Beckley, WV and its General Motors dealership in Beckley, WV and will pursue entering into new sale agreements in connection with these Dealerships within the coming weeks.We continue to believe that our stock price does not reflect the net asset value of our company and believe that this transaction along with the sale of our remaining assets will enable us to maximize stockholder value.The Company further announced that it is continuing to move forward with the Plan of Liquidation allowing the Company to sell all of the Company's assets, distribute the net proceeds to stockholders and dissolve the Company. "The Board and the management team all believe that, given the diversified nature of our portfolio, pursuing multiple transactions with different potential buyers for assets or groups of assets presents the best opportunity to maximize stockholder value as well as to maximize the net proceeds to be distributed to shareholders upon completion of the Plan of Liquidation," said Sam Tawfik, Chief Executive Officer and Chairman.

16:09 EDT Four Corners Property Trust acquires Tires Plus property for $2.1M - Four Corners Property Trust announces the acquisition of a Tires Plus property for $2.1 million. The property is located in a strong retail corridor in Ohio and is corporate-operated under a triple net lease with approximately 5 years of term remaining and annual rent increases of 2%. The transaction was priced at a 6.5%, exclusive of transaction costs.

16:09 EDT Tesla says Q3 'another strong quarter' with 'record revenue' - Tesla said in its quarterly update letter: "The third quarter of 2022 was another strong quarter with record revenue, operating profit and free cash flow." In the last 12 months, our free cash flow exceeded $8.9B. Our operating margin reached 17.2% in Q3."

16:07 EDT Knight-Swift sees overall consumer moderating in Q4 - In Q4, the company sees: "Minimal non-contract opportunities, Muted peak season, Strong demand continues for trailer pools, Small carriers continue to exit as a result of lower spot rates and significantly higher operating costs, LTL demand remains stable with continued increases in revenue per hundredweight yearover-year, Labor availability improves for stronger carriers, Inflationary pressures continue for equipment, maintenance, labor and other cost items, Demand for used equipment market weakens as small carriers struggle."

16:06 EDT Kinder Morgan raises quarterly dividend 3% to 27.75c per share - Kinder Morgan, Inc.'s board of directors today approved a cash dividend of $0.2775 per share for the third quarter ($1.11 annualized), payable on November 15, 2022, to stockholders of record as of the close of business on October 31, 2022. This dividend is a 3% increase over the third quarter of 2021.

15:26 EDT Nestle reports 5.11% passive stake in ChromaDex - In a regulatory filing, Nestle (NSRGY) disclosed a 5.11% stake in ChromaDex (CDXC), representing 3,816,794 shares. The filing does not allow for activism.

14:03 EDT Heartland Financial raises quarterly dividend to 28c from 27c - Heartland Financial USA announced its board approved a quarterly cash dividend of 28c per share of the company's common stock, an increase of 1c, payable on November 29, to stockholders of record at the close of business on November 14.

13:42 EDT Tutor Perini announces subsidiary awarded federal contracts valued at $164M - Tutor Perini announced that its subsidiary, Perini Management Services, Inc. , or PMSI, has been awarded three fixed-price federal contracts collectively valued at approximately $164M. The combined contract values will be included in the company's third-quarter 2022 backlog.

13:03 EDT Moderna announces CHMP issues positive opinion on bivalent vaccine - Moderna announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion recommending conditional marketing authorization for mRNA-1273.222, Spikevax bivalent Original/Omicron BA.4-5, as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, who have previously received at least a primary vaccination course against COVID-19. "Following the CHMP's positive opinion, the European Commission will make an authorization decision on the use of Spikevax bivalent Original/Omicron BA.4-5. This vaccine now joins Moderna's other updated booster vaccine, mRNA 1273.214, that targets the BA.1 variant, for use in individuals 12 years and older," the company stated.

12:41 EDT Moderna announces CHMP issues positive opinion on variation to Spikevax CMA - Moderna announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has issued a positive opinion recommending a variation to the conditional marketing authorization, or CMA, to include a 25 B5g two-dose series of Spikevax, mRNA-1273, for active immunization to prevent coronavirus disease 2019 caused by SARS-CoV-2 in children 6 months to 5 years. Following the CHMP's positive opinion, the European Commission will make an authorization decision on the use of Spikevax in children ages 6 months to 5 years. "This recommendation by the CHMP reaffirms the effectiveness and safety of mRNA-1273 and provides parents across Europe with another option to protect their young children against COVID-19, a group at high risk of infection and where additional health prevention measures may not always be feasible," said Stephane Bancel, Moderna's CEO. "We are grateful to the CHMP for their review and look forward to an authorization decision from the European Commission."

12:05 EDT Intel announces new cloud collaboration with HashiCorp - Intel (INTC) announced a new collaboration with HashiCorp (HCP) "to help customers accelerate their cloud journey and optimize the cost, performance and security of their cloud workloads." HashiCorp provides open source and commercial products that enable developers, operators and security professionals to provision, secure, connect and run cloud-computing infrastructure through automation, Intel said in a statement. Together, the companies will provide developers with Sentinel policy recommendations leveraging built-in Intel Xeon Scalable accelerators to optimize workloads and improve the return on investment of their cloud strategy, it added. Reference Link

12:00 EDT Carvana falls -14.2% - Carvana is down -14.2%, or -$2.61 to $15.76.

12:00 EDT Generac falls -21.9% - Generac is down -21.9%, or -$32.41 to $115.33.

12:00 EDT Zymeworks rises 18.9% - Zymeworks is up 18.9%, or $1.06 to $6.67.

11:47 EDT Pfizer, BioNTech report positive CHMP opinion on Comirnaty in kids over 6 months - Pfizer (PFE) and BioNTech SE (BNTX) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended marketing authorization for a 3-microgram dose of Comirnaty COVID-19 vaccine, mRNA, which is based on the wild-type spike protein of SARS-CoV-2, as a three-dose series for children ages 6 months to less than 5 years, also referred to as 6 months through 4 years of age. "The European Commission will review the CHMP recommendation and is expected to make a final decision soon," the companies said.

11:46 EDT Chegg appoints Nathan Schultz as COO, effective immediately - Chegg announced the promotion of Nathan Schultz to COO, effective immediately. Schultz has served in various roles at Chegg for 15 years, and was previously President of Learning Services, where he was responsible for all aspects of Chegg's learning tools. In the newly created role, Schultz will drive the expansion and further integration of Chegg's direct-to-student services including learning services, non-academic support, and career skills training, the company said in a statement. "Nathan has been a transformational leader at our company for many years, and on behalf of myself, his colleagues, and our Board of Directors, we are all delighted he is taking on the role of COO," said Dan Rosensweig, CEO and President of Chegg.

11:43 EDT Novonix selected for $150M grant from U.S. DOE - Novonix Limited announced that its Novonix Anode Materials division was selected to enter negotiations to receive $150M in grant funding from the U.S. Department of Energy to expand its domestic production of high-performance, synthetic graphite anode materials. "This award, announced by President Biden, strengthens the North American battery supply chain amidst surging demand and growing calls to onshore these critical industries. Negotiations will cover final conditions including operational milestones and timing and schedule of payment of grant funds... The funding announced today by the Department of Energy is the first phase of over $7 billion in total provided by the President's Bipartisan Infrastructure Law for the battery supply chain and supports NOVONIX's execution of its strategic growth plan for synthetic graphite anode materials produced in the U.S. Specifically, the grant funds will be dedicated to the construction of a 30,000 tonnes per annum U.S. manufacturing facility, including site selection, plant layout, and engineering design with capability for additional expansion," the company stated.

11:31 EDT Microvast, Albemarle among infrastructure law funding recipients - The Biden-Harris Administration, through the U.S. Department of Energy, earlier today announced the first set of projects funded by the President's Bipartisan Infrastructure Law to expand domestic manufacturing of batteries for electric vehicles, or EVs, and the electrical grid and for materials and components currently imported from other countries. "The 20 companies will receive a combined $2.8 billion to build and expand commercial-scale facilitiesin 12 states to extract and process lithium, graphite and other battery materials, manufacture components, and demonstrate new approaches, including manufacturing components from recycled materials. The Federal investment will be matched by recipients to leverage a total of more than $9 billion to boost American production of clean energy technology, create good-paying jobs, and support President Biden's national goals for electric vehicles to make up half of all new vehicle sales by 2030 and to transition to a net-zero emissions economy by 2050," the DOE stated. Among the 20 recipient companies listed were Microvast (MVST), Albemarle (ALB), Piedmont Lithium (PLL) and Applied Materials (AMAT). Reference Link

11:16 EDT EMA recommends approval of second adapted Spikevax vaccine - EMA's human medicines committee, or CHMP, has recommended authorizing an adapted Spikevax COVID-19 vaccine targeting the Omicron subvariants BA.4 and BA.5 in addition to the original strain of SARS-CoV-2. "The adapted vaccine, Spikevax bivalent Original/Omicron BA.4-5, is recommended for adults and children from 12 years of age who have already had a primary vaccination course against COVID-19. This is the second adapted Spikevax vaccine that EMA has recommended for approval. An adapted Spikevax vaccine targeting Omicron BA.1 and the original strain was authorized in September 2022," the EMA stated. Reference Link

11:14 EDT EMA recommends approval of Comirnaty, Spikevax for children over 6 months - EMA's human medicines committee, or CHMP, has recommended extending the use of Pfizer (PFE) and BioNTech's (BNTX) Comirnaty and Moderna's (MRNA) Spikevax targeting the original strain of SARS-CoV-2. The Committee recommended including the use in children aged 6 months to 4 years for Comirnaty and use in children aged 6 months to 5 years for Spikevax. Comirnaty and Spikevax are already approved in both adults and children aged from 5 and 6 years, respectively. Reference Link

11:11 EDT ERNA Stock trading halted, volatility trading pause

11:05 EDT Pinnacle Financial sees 'low 20%" EOP loan growth for FY22 - Estimates cumulative loan beta will settle around 60% for 2022. GAAP net interest income growth for 2022 is estimated to be low 20s percentage growth from 2021. Fee growth should approximate high-single digit percentage growth. The company is "confident" in its model to produce outsized revenue and earnings growth. Comments taken from Q3 earnings conference call presentation slides.

11:03 EDT L3Harris invests in Seasats for autonomous maritime capabilities - L3Harris Technologiesannounced a strategic investment in Seasats, a privately-owned company involved in the design and production of low-cost, solar-powered maritime autonomous surface vehicles for military and commercial use. L3Harris is making its investment to fuel collaborative development and accelerate production of Seasats' X3 micro-ASV, whose unique design and low-signature waterline makes it difficult to detect by sight and radar. The X3 features stealthy performance and reliable six-month endurance in all weather conditions for a fraction of the price of current small maritime ASVs, and provides a complement to L3Harris' large and medium-sized ASV offerings.

10:52 EDT United Airlines: Entering Q4 with a lot of momentum

10:43 EDT United Airlines notes 'permanent structural change' in leisure demand - There has been a permanent structural change in leisure demand because of the flexibility that hybrid work allows, United Airlines said.

10:39 EDT United expects to hire 15,000 new team members this year, 15,000 next year

10:34 EDT United Airlines CEO: Air travel 'still in Covid recovery' - CEO Scott Kirby says hybrid work gives "freedom and flexibility to travel for leisure more often."

10:15 EDT Green Organic Dutchman enters agreement to merge with BZAM - The Green Organic Dutchman Holdings and BZAM Holdings announced that they have entered into a binding and definitive share exchange agreement dated October 18, 2022 with BZAM's sole shareholder, pursuant to which TGOD will acquire all of the issued and outstanding common shares of BZAM from the BZAM Shareholder, in exchange for common shares of TGOD. The Transaction will result in the BZAM Shareholder ultimately holding an approximate 49.5% of the issued and outstanding Combined Entity Shares upon closing of the Transaction, with the ability to earn additional Combined Entity Shares subject to achievement of certain financial milestones in 2023. The combined entity resulting from the Transaction is estimated to be the sixth largest Canadian cannabis company based on June to August 2022 retail sales, with scale and breadth across major provinces and a complete portfolio of market leading brands and products. The combination of BZAM and TGOD is expected to deliver at least C$10M of annualized cost synergies within the first three quarters following completion of the Transaction, aiding in the achievement of positive adjusted earnings before interest, taxes, depreciation and amortization by mid 2023. The Combined Entity expects to achieve cost synergies in the key areas of cultivation and production, cannabis and product purchasing, sales, marketing and corporate expenses. BZAM's Pitt Meadows, British Columbia facility will also provide TGOD with low-cost THC distillate and extraction capabilities, which is expected to improve cannabis 2.0 product margins. The Combined Entity expects to share a unified sales force leading to improvements of geographical coverage and increased retail distribution. The Transaction is expected to result in a stronger balance sheet and provide the Combined Entity with access to lower cost capital. Upon completion of the Transaction, BZAM's current CEO Matt Milich, and CCO, Jordan Winnett, will lead the Combined Entity as CEO, CCO, along with TGOD's current CEO and Interim CFO Sean Bovingdon, who will take the role of CFO, in order to assist with the integration of BZAM and TGOD and the transitionary period of the Combined Entity. The board of directors of the Combined Entity will consist of seven members including five members from TGOD's existing board of directors, and two members nominated by BZAM. In consideration for all the issued and outstanding common shares of BZAM, upon Closing, TGOD will issue Combined Entity Shares to the BZAM Shareholder in two tranches, totalling an approximate 49.5% ownership stake of the Combined Entity. In addition, the BZAM Shareholder is also entitled to earn up to C$33M in Combined Entity Shares, subject to achievement of certain Milestones. The Milestones include payouts of Milestone Shares tied to annual net revenue targets and positive adjusted EBITDA targets for 2023. The Transaction is scheduled to close on or about November 3, 2022, subject to a number of customary conditions being satisfied or waived. Each Milestone Share shall be issued at a deemed price of the greater of C$0.0596, that being the 15-day volume weighted average price of the common shares of TGOD immediately prior to the date the Agreement was signed, and the minimum price permitted under the policies of the Canadian Securities Exchange. In accordance with the terms of the Agreement, the BZAM Shareholder will enter into a contractual lock-up agreement, whereby the Combined Entity Shares received as part of Closing and excluding the Milestone Shares, shall be subject to escrow with 1/3 of such Escrowed Shares being released on the 4-month, 8-month, and 12-month anniversaries of the date such Escrowed Shares are issued.

10:08 EDT Amprius Technologies trading halted, volatility trading pause

10:00 EDT M&T Bank falls -10.3% - M&T Bank is down -10.3%, or -$19.45 to $169.91.

10:00 EDT Generac falls -21.3% - Generac is down -21.3%, or -$31.53 to $116.21.

10:00 EDT Amprius Technologies rises 10.0% - Amprius Technologies is up 10.0%, or 62c to $6.83.

09:59 EDT Abbott says 'don't need to do M&A,' but lots of opportunities exist

09:53 EDT Ally Financial sees Q4 as earnings 'low point'

09:47 EDT Winnebago falls -10.4% - Winnebago is down -10.4%, or -$6.25 to $53.94.

09:47 EDT Traeger rises 4.7% - Traeger is up 4.7%, or 14c to $3.11.

09:47 EDT Zymeworks rises 7.5% - Zymeworks is up 7.5%, or 42c to $6.03.

09:44 EDT LMF Acquisition Opportunities Inc trading resumes

09:29 EDT Martin Midstream Partners enters joint venture with Samsung C&T America, Dongjin - Martin Midstream Partners announced that, through an affiliate Martin ELSA Investment, it has entered into definitive agreements with Samsung C&T America and Dongjin USA, an affiliate of Dongjin Semichem to form DSM Semichem. DSM will produce and distribute electronic level sulfuric acid, or ELSA. By leveraging the existing assets of MMLP located in Plainview, Texas and installing additional facilities as required, DSM will produce ELSA that meets the strict quality standards required by the recent advances in semiconductor manufacturing. In addition to owning a 10% non-controlling interest in DSM, the partnership will be the exclusive provider of feedstock to the ELSA facility. MMLP, through its affiliate Martin Transport, Inc., will also provide land transportation services to end-users of the ELSA produced by DSM. Assuming growth capital investments of approximately $20M, the partnership expects to realize annual distributable cash flow of $5M to $6M from both the improvements to the existing assets and its interest in DSM. The ELSA facility is estimated to start-up in the first quarter of 2024.

09:27 EDT Medigus says ScoutCam appoints Yehu Ofer as CEO - Medigus announced today that ScoutCam announced the appointment of Yehu Ofer as CEO, effective immediately. Mr. Ofer, a former Israeli Air Force pilot and commander, as well as a leading professional in the aviation and aerospace industries, will lend his decades of experience to ScoutCam's continued growth and success.

09:22 EDT Cullman Bancorp adopts 550,000 share stock repurchase program - Cullman Bancorp announced that its Board of Directors has adopted a stock repurchase program. Under the repurchase program, the Company may repurchase up to 550,000 shares of its common stock, or approximately 7.5% of the current outstanding shares. Repurchases will be made no sooner than the termination of the Company's regular trading blackout period, and consistent with the Company's trading policies. The repurchase program permits shares to be repurchased in open market or private transactions, through block trades, and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission.

09:21 EDT American Express, Cvent team up on virtual payment capabilities - American Express (AXP) and Cvent (CVT) introduced enhanced features to the Cvent Event Marketing and Management platform that further expand virtual payment capabilities, leveraging American Express' integrated budget management and payment automation solutions.

09:20 EDT MidWestOne appoints Charles Reeves as CEO - MidWestOne Financial Group announced that its Board of Directors has named Charles Reeves as its new CEO effective November 1, 2022. Reeves succeeds Charlie Funk, who is retiring following a 22-year career with the organization. Funk will remain with MidWestOne through April 2023 as a special advisor to ensure a seamless transition, and he will continue to serve as a director on the Company's Board of Directors. Most recently, Reeves served as President, CEO and Director of Beach Bancorp.

09:18 EDT Spirit Airlines stockholders approve merger agreement with JetBlue - Spirit Airlines (SAVE) announced that its stockholders approved the merger agreement with JetBlue Airways (JBLU). Based on the preliminary voting results provided by the independent inspector of election at the special meeting of stockholders held today, more than 50% of the outstanding shares of Spirit common stock voted in favor of the transaction. The final voting results of the special meeting, as tabulated by an independent inspector of elections, will be filed on a Form 8-K with the U.S. SEC. The completion of the transaction is subject to customary closing conditions, including receipt of required regulatory approvals. Spirit and JetBlue expect to conclude the regulatory process and close the transaction no later than the first half of 2024. Barclays and Morgan Stanley & Co. are serving as financial advisors to Spirit, and Debevoise & Plimpton and Paul, Weiss, Rifkind, Wharton & Garrison are serving as legal advisors.

09:16 EDT Green Thumb to launch "RISE Express" dispensaries in Florida - Green Thumb Industries announced plans to expand its medical retail footprint in Florida through a lease agreement with Circle K. Starting in 2023, Green Thumb plans to launch its test and learn phase of the rollout with approximately ten "RISE Express" branded dispensaries adjacent to Circle K stores in various Florida locations. Through the exclusive agreement, Green Thumb can lease space from Circle K in Florida, where the retailer currently operates approximately 600 locations. The "RISE Express" stores will offer patients a selection of branded cannabis products including RYTHM premium flower, Dogwalkers pre-rolls, incredibles gummies and &Shine vapes. The products available at these retail stores will come from the Company's new 28-acre cultivation facility in Ocala that will be operational by the end of 2022. Green Thumb entered the Florida market in 2018 and currently owns and operates medical cannabis retail stores in Bonita Springs, Deerfield Beach, Hallandale Beach, Kendall, Oviedo, Pinellas Park and West Palm Beach. The Company also has an existing cultivation and processing facility in Homestead.

09:13 EDT Abbott says macro economic conditions 'remain challenging' - Says inflation remains an issue. Says international sales impacted by "transitory items." Comments taken from Q3 earnings conference call.

09:12 EDT Ibex to sponsor Execs In The Know event - ibex announced its sponsorship of the Customer Response Summit - Coronado, CA, an Execs In The Know event, October 24-26, 2022. ibex will also host an invitation-only dinner for CX leaders and industry influencers on October 24.

09:10 EDT Telesis Bio, Cellibre announce collaboration on development of BioXp DBC - Telesis Bio and Cellibre announced initiation of work under a collaboration to optimize the development and validation of Telesis Bio's BioXp Digital-to-Biological Converter instrument for fully automated manufacturing of on-demand CRISPR-Cas9 guide RNA for genome editing. By integrating Telesis Bio's short oligonucleotide ligation assembly enzymatic DNA synthesis technology directly onto its recently released BioXp 9600 system, the BioXp DBC instrument empowers scientists with same-day design and build capabilities for their guide RNAs, and without the need to order custom reagents. The gRNA synthesis kit is the first of several BioXp DBC kits the company has planned. "We believe our SOLA EDS solution is the enabling technology for the Digital-to-Biological Converter, or DBC, and it starts with its integration on our recently released BioXp 9600 system," said Todd Nelson, PhD, CEO of Telesis Bio. "We look forward to working with the Cellibre team to validate and enhance our automated BioXp DBC solution for generating CRISPR-Cas9 guide RNA on demand."

09:09 EDT Qualigen Therapeutics announces two posters on RAS-targeted inhibitor program - Qualigen Therapeutics announces the presentation of two posters detailing the Company's RAS-Targeted platform at the National Cancer Institute-sponsored Fourth RAS Initiative Symposium to be held October 17-19, 2022 at The Advanced Technology Research Facility of the National Cancer Institute in Frederick, Maryland. Poster highlights included: Title: "A novel pan-RAS inhibitor for Malignant Peripheral Nerve Sheath Tumors": Following screening to identify an initial candidate inhibitor of RAS oncoproteins for malignant peripheral nerve sheath tumors, investigators measured in vitro and in vivo activity against these tumors. The lead candidate, designated by investigators as RAS-F suppressed RAS signaling pathways and suppressed MPNST tumor growth in animal models. Title: "A Novel RAS Inhibitor for Pancreatic Cancer": Following screening to identify an initial candidate inhibitor against pancreatic cancer tumor growth, investigators analyzed in vitro and in vivo activity against these tumors. The lead candidate, designated RAS-F, suppressed RAS signaling pathways and pancreatic tumor cell growth in vitro. It also suppressed xenograft development of human and mouse RAS-driven pancreatic tumor cell lines and reduced the growth of pancreatic cancer patient-derived xenograft models. The study also showed that RAS-F enhanced the effects of immune checkpoint therapy in syngeneic tumor xenografts.

09:08 EDT Noah Holdings provides update on voluntary conversion of listing status - Noah Holdings provides an update on the Company's proposed voluntary conversion of its secondary listing status on The Main Board of The Stock Exchange of Hong Kong to dual-primary listing. Application for Voluntary Conversion to Dual Primary Listing. The Company has applied to the Hong Kong Stock Exchange with respect to the Primary Conversion. On October 19, 2022, the Company received the acknowledgement from the Hong Kong Stock Exchange in respect of the application of Primary Conversion. The Effective Date on which the Primary Conversion will become effective is expected to be on or before December 31, 2022. Upon the Effective Date, the Company will be dual primary listed on the Hong Kong Stock Exchange and the New York Stock Exchange. Proposed Grant of Issuance Mandate and Repurchase Mandate. Ordinary resolutions will be proposed at the annual general meeting of the Company to be convened on or around December 6 to approve the grant of an issuance mandate to the directors of the Company to allot, issue or deal with Class A ordinary shares of the share capital of the Company with a par value of 00.05c each, or securities convertible into Shares and/or American depositary shares, not exceeding 20% of the total number of issued Shares as of the date of the First GM; and a repurchase mandate to the Directors to repurchase Shares not exceeding 10% of the total number of issued Shares and/or ADSs as of the date of the First GM.

09:06 EDT Remark Holdings appoints DeMeakey Williams, Sr. as Chief Revenue Officer - Remark Holdings announced that DeMeakey Williams, Sr. joins the organization as Chief Revenue Officer, where he will oversee Remark's revenue generation, brand awareness, go-to-market strategies, global communications program, demand creation and customer advocacy. DeMeakey Williams, Sr. brings more than 20 years of marketing, sales and innovation experience from established publicly traded companies and high-growth start-up brands to Remark. Before Remark, DeMeakey held the position of Vice President of America's Sales at Pangiam, a security technology firm, taking responsibility for their corporate sales and business development within the Western Hemisphere.

09:05 EDT Super Apps enters merger agreement with Technology & Telecommunication - Super Apps Holdings and Technology & Telecommunication Acquisition Corporation announced that they have entered into a definitive agreement and plan of merger for a business combination that will result in Super Apps becoming a publicly listed company. Upon closing of the transaction, the combined company will be named TETE Technologies Inc. and is expected to remain listed on the Nasdaq Stock Market under the ticker symbol, "TETE". The transaction reflects an estimated pro forma enterprise value for the combined company of approximately $1.1 billion. Super Apps entered into a share sale agreement with MobilityOne, a wholly-owned subsidiary of AIM quoted MobilityOne Limited, pursuant to which Super Apps agreed to purchase 60% of MobilityOne's ownership interest in OneShop Retail in a transaction which will close prior to the consummation of the Business Combination. MobilityOne has developed an end-to-end e-commerce solution which connects various service providers across several industries such as banking, telecommunication and transportation through multiple distribution channels such as electronic data capture terminals, short messaging services, automated teller machines and Internet banking services. MobilityOne currently has ownership of the intellectual property that OneShop Retail uses in its operations and, in connection with the closing of the Business Combination, MobilityOne will grant OneShop Retail a long term license for use of such intellectual property. MobilityOne's technology platform is flexible, scalable and has been designed to facilitate cash, debit card and credit card transactions from multiple devices while controlling and monitoring the distribution of different products and services. Super Apps and MYISCO, entered into a collaboration agreement, which shall become effective upon closing of the Business Combination, allowing OneShop Retail, as the authorized bill payment collection and credit lending agency of ANGKASA, to operate its payment collection system through ANGKASA's authorized dealers for the collection and remission of any payment of bills via cash payment, credit card, debit card or cheque. ANGKASA currently facilitates the monthly salary disbursements of its members under its salary deduction scheme. Based upon the Company's anticipated collaboration with MYISCO and other potential collaborations, the combined company projects revenue of approximately $348 Million for the financial year ending December 31, 2023. The proceeds from this transaction will enable Super Apps to build out its technology infrastructure to support demand from blue chip customers in the fast-growing e-commerce payment solutions market and enhance revenue. As part of the deal, Super Apps will retain its experienced management team, led by CEO Loo See Yuen, while gaining new board members, and Loke Chow Wing, from the TETE team. Pursuant to the Merger Agreement, Super Apps will merge with TETE Technologies Sdn Bhd, a Malaysian private limited company and wholly owned subsidiary of TETE, with Super Apps surviving and TETE acquiring 100% of the equity securities of Super Apps. In exchange for their equity securities, the shareholders of Super Apps will receive an aggregate number of ordinary shares of TETE with an aggregate value equal to: one billion one hundred million U.S. Dollars , minus any Closing Net Indebtedness of which $235,000,000 will be paid at the closing of the Business Combination with the remaining $865,000,000 subject to the earn-out provisions set forth in the Merger Agreement.The Business Combination has been approved by the boards of directors of each of TETE and Super Apps. The Business Combination will require the approval of the shareholders of TETE and Super Apps and is subject to other customary closing conditions, including a proxy statement being filed with and cleared by the U.S. Securities and Exchange Commission. The transaction is expected to close in the first half of 2023.

09:04 EDT Uber launches advertising division, unveils Uber Journey Ads - Uber has formally launched its advertising division and unveiled Uber Journey Ads, a way for brands to connect with consumers throughout the entire ride process. Journey Ads are the latest initiative from a dedicated team formed at Uber this year under advertising veteran Mark Grether. Leveraging Uber's first-party data and insights across its mobility and delivery businesses presents companies with new surfaces and closed-loop attribution to reach Uber's audience of 122M monthly active users. With the addition of Journey Ads, Uber has created an engaging model that enables brands to share strategic campaigns across Uber's mobility and delivery businesses, while connecting with consumers in brand-safe and captivating ways. Journey Ads place relevant brand content and offers in front of purchase-minded audiences as they transact throughout their journey - while waiting for their driver and during their trip.

09:01 EDT Plug Power, FreezPak logistics expand agreement to supply fuel cells - Plug Power announced an agreement with FreezPak Logistics to provide fuel cells and hydrogen storage and fueling infrastructure to nine additional sites and nearly 400 lift trucks. The multi-site agreement makes FreezPak Logistics a pedestal customer. The agreement includes providing hydrogen infrastructure and fuel cells for lift trucks at four existing FreezPak Logistics sites, along with five additional sites scheduled for 2023. In total, Plug will support 11 customer sites across the U.S, including the three sites already in operation. m"FreezPak Logistics has been a longstanding believer in Plug's innovative technology and hydrogen fuel cells," Andy Marsh, Plug CEO, said. "We are thrilled to expand our partnership, which further improves the American supply chain and decreases carbon emissions."

08:59 EDT Establishment Labs sinks 18% after Hindenburg short report

08:56 EDT Insmed announces three strategic financings totaling $775M - Insmed announced three strategic financings resulting in aggregate gross proceeds of $775M. Proceeds from the transactions will strengthen Insmed's financial position, which will place the Company in a position to deliver clinical data from each of its four pillars. Insmed has entered into a $350M senior secured term loan agreement with funds managed by Pharmakon Advisors, a leading investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds. The five-year Term Loan matures in October 2027. The Term Loan bears interest at a rate based upon the secured overnight financing rate, or SOFR, subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. The Company has also entered into a $150M secured royalty financing agreement with OrbiMed, a leading investor in the healthcare industry. Under the agreement, OrbiMed will be entitled to receive royalties of 4% on global net sales of ARIKAYCE until September 1, 2025, and royalties of 4.5% on ARIKAYCE global net sales from September 1, 2025, as well as royalties of 0.75% on brensocatib global net sales. The total royalty payable by Insmed to OrbiMed is capped at 1.8x of the purchase price up to a maximum of 1.9x of the purchase price under certain conditions. The Term Loan and the Royalty Financing will be secured by an all-assets collateral package that is governed by the terms of an intercreditor agreement entered into among BioPharma Credit, as collateral agent, OrbiMed Royalty & Credit Opportunities IV, LP and Insmed. Transactions for both the Term Loan and Royalty Financing closed on October 19. SVB Securities acted as an exclusive financial advisor to Insmed on the Term Loan and Royalty Financing. Covington & Burling acted as counsel to Insmed on the Term Loan and Royalty Financing. Akin Gump Strauss Hauer & Feld acted as counsel to Pharmakon Advisors, LP on the Term Loan. Morrison & Foerster acted as counsel to OrbiMed on the Royalty Financing.

08:51 EDT Cnooc says Baodao 21-1 gas field passes Chinese governmental review - Cnooc announced that the proved gas in-place of Baodao 21-1 Gas Field has successfully passed the Chinese governmental review and filing. Baodao 21-1 gas field is located in Baodao Sag, Qiongdongnan Basin, Western South China Sea. The water depth ranges from 660 to 1,570 meters. The main gas-bearing layer is the Paleogene Lingshui formation and the discovery is condensate gas reservoirs. The discovery well Baodao 21-1-1 completed at hole depth of 5,188 meters, encountering 113 meters of pay zone. The well is tested to produce an average of 587,000 cubic metres of natural gas per day. Chinese governmental bodies reviewed the discovery and certified the proven in-place of natural gas and condensate oil at over 50 billion cubic metres and 3 million cubic metres respectively.Baodao 21-1 gas-bearing structure will host the first deep-water deep-stratum large gas field in the South China Sea, realising the biggest discovery in more than half a century in Songnan-Baodao Sag. It will lay a solid foundation for the construction of a gas production base of trillion cubic meters resources in the South China Sea. The review and filing once again confirmed the exploration potential of this structure.

08:49 EDT P&G to offset some cost headwinds with price increases, productivity savings

08:43 EDT NanoVibronix: Nasdaq grants continued listing subject to $1.00 bid requirement - NanoVibronix announced that on October 17, a Nasdaq Hearings Panel granted the Company's request for continued listing on The Nasdaq Capital Market, subject to the Company's satisfaction of certain conditions, including the provision of an update to the Panel on December 15, , regarding the Company's efforts to evidence compliance with the $1.00 bid price requirement for continued listing on Nasdaq. Following the submission of such update, the Panel will consider the Company's request for a further extension. The Panel has the authority to grant the Company an extension through February 23, 2023, in accordance with the Nasdaq Listing Rules. As set forth in the preliminary proxy statement filed by the Company with the Securities and Exchange Commission on October 13 at the annual meeting to be held on December 15 the Company will seek shareholder approval for the implementation of a reverse stock split if necessary and at the Board's discretion to regain compliance with Nasdaq's price requirement.

08:39 EDT MaxLinear, SoftAtHome team on prpl LCM solution for home gateways - MaxLinear announced that it has teamed with SoftAtHome to showcase the prpl Life Cycle Management at the prpl Foundation 2022 prpl Summit. The open-source LCM agent software developed for prplOS will be shown running on the MaxLinear AnyWAN Open Service Platform connected to SoftAtHome's LCM Backend solution.The MaxLinear and SoftAtHome solution demonstrates a new choice for operators that provides simplicity of development and faster time to market for home gateways by remotely downloading and managing the same services for different hardware platforms through the same backend server. The LCM uses containers and prplOS high-level APIs, including the mechanisms defined by the Broadband Forum TR-369 standard.

08:37 EDT Onion Global generated RMB12M in GMV within the first three days of promotion - Onion Global announced that it generated over RMB12M in GMV within the first three days of its 2022 Luca Brand Seasonal Promotion. The sales promotion offered discount coupons for quality products from premium brands, creating a fun, engaging, and affordable shopping experience tailored to the diverse demands of younger consumers. During the promotion, Onion Global used live games to engage with consumers and build awareness of the LUCA brands. Onion Global's platform O'Mall subsidized popular and trending products from LUCA brands through a variety of preferential discounts covering both international and domestic orders during the period. The eight-day seasonal promotion, under the theme "Luca Brand New Players", started on October 12 and continued until October 19.

08:36 EDT Sun Nuclear partners with Accuray to develop new Quality Management solutions - Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies (MIR) ("Mirion"), announced that it is developing new Quality Management solutions, in collaboration with Accuray (ARAY), for the company's Radixact System with Synchrony, which enables real-time, personalized adaptive radiation therapy. Initial innovations from the collaboration will be featured in the Sun Nuclear booth at the ASTRO Annual Meeting, October 23-25, 2022, in San Antonio, Texas.

08:35 EDT Badger Meter says demand environment remains robust - Bockhorst added, "The demand environment remains robust as customers continue to adopt our digital smart water solutions that deliver efficiency, resiliency, and sustainability to address the variety of underlying secular challenges the water industry faces. Our success in selling our broad 'choice-matters' water quality and quantity offerings continue to illustrate the benefits of our differentiated, flexible and comprehensive smart water AMI solutions. This commercial excellence, combined with nimble execution have demonstrated our ability to navigate persistent macro challenges and drive outperformance. Our strong order pace and bid funnel, combined with the value-based pricing actions we have taken throughout this unprecedented inflationary environment, are supportive of revenue growth and margin expansion throughout economic cycles. Robust cash flow and ample credit availability provide us with the financial flexibility to execute our capital allocation priorities, including the recent increase in the annual dividend, and continued investments in growth. Badger Meter is well-positioned to continue its track record of profitable growth enhanced by our innovative offerings, end market resiliency and differentiated execution. We believe this combination, along with our durable business model aligned with our vision to preserve and protect the world's most precious resource, will generate positive shareholder value over the long term."

08:34 EDT SaverOne 2014 signs firs MOU with truck manufacturer, Iveco - SaverOne 2014 announced that in line with its long-term growth strategy, it has signed a memorandum of understanding with truck manufacturer, Iveco, for integrating its solution within Iveco's trucks, to prevent driver distraction from cellphone use. The parties aim to sign a formal agreement before year-end. Iveco is a global vehicle manufacturer headquartered in Italy, which is focused on light, medium and heavy commercial vehicles. It sells approximately 150,000 vehicles globally on an annual basis, via its five thousand sales and service outlets across over 160 countries. During 2023, under the MOU, Iveco and SaverOne will cooperate to integrate SaverOne's protection solution into Iveco trucks during the manufacturing process. Starting in 2024, Iveco is expected to offer its new trucks, equipped with SaverOne's driver distraction protection technology, to its global customer base.

08:32 EDT Sysorex announces closing of $500,000 private placement - Sysorex announced that it has entered into a securities purchase agreement with accredited investors to purchase approximately $500,000 of its shares of common stock and warrants to purchase common stock in a private placement transaction.

08:32 EDT Neurocrine announces data from patients on prescribed benztropine - Neurocrine Biosciences announced data on the real-world comorbidities, polypharmacy, and treatment patterns of patients on newly prescribed benztropine who were also being treated with antipsychotic medications. This research will be presented at the 2022 American Psychiatric Nurses Association, or APNA, Annual Conference being held October 19-22 both virtually and in Long Beach, CA. The new findings are from a retrospective 24-month observational study of claims between January 1, 2017, and March 30, 2020. Benztropine is an anticholinergic medication approved as an adjunct for treatment of all forms of parkinsonism, including drug-induced parkinsonism that causes movement problems similar to those seen in Parkinson's disease, such as tremors, slow movement, and stiffness. Benztropine can also be used to control other antipsychotic-induced movement disorders, except for tardive dyskinesia, or TD. The analysis found that the patient population, who received at least one new benztropine prescription during the study, often had multiple comorbidities, substantial polypharmacy, and mild, moderate, or severe anticholinergic burden associated with the medications patients were taking prior to initiation of benztropine.

08:32 EDT Moderna announces clinical data on mRNA-1273.214 bivalent booster - Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50 microgram booster dose of mRNA-1273.214 elicited a superior neutralizing antibody response against Omicron BA.1 when compared to a 50 microgram booster dose of mRNA-1273 in all participants regardless of prior infection. Superior performance against Omicron BA.1 was also durable, with higher antibody titers sustained through three months. In addition, mRNA-1273.214 demonstrated significantly higher neutralizing antibody responses against Omicron BA.4/BA.5 compared to mRNA-1273 28 days after administration, as previously reported. Potent responses were also seen against Omicron BA.2.75 28 days after administration, suggesting that the bivalent booster elicits broad cross-neutralization against Omicron variants. Observed side effects of mRNA-1273.214 were similar or less severe than those of either a second or third dose of the original vaccine. Additionally, no new safety concerns were identified in the three-month follow-up. The complete data set will be presented during a breakout session on October 20, 2022 at ID Week. In addition, data will be submitted for peer-reviewed publication and shared with regulators around the world. The Company expects interim safety and immunogenicity results of its Omicron BA.4/BA.5-targeting bivalent vaccine, mRNA-1273.222, to become available later this year. Data will be generated from a clinical study designed in accordance with regulatory guidance for bivalent booster vaccines against COVID-19.

08:28 EDT SOBR Safe says commercial construction company implementing SOBRcheck - SOBR Safe announced that a prominent west coast commercial construction company is implementing SOBRcheck as the new front line alcohol screening solution for its more than 400 employees across multiple locations. The construction company is an established customer of SOBRsafe distributor Butterfield Onsite Drug Testing, and its conversion to SOBRsafe's advanced safety technology validates the Company's sales strategy.

08:24 EDT ProPhase Labs announces collaboration with G42 Healthcare - ProPhase Labs announced that its wholly-owned subsidiary, ProPhase Precision Medicine, has signed a Memorandum Of Understanding, MOU, with G42 Healthcare to explore several collaborative opportunities including, but not limited to, genomic sequencing, artificial intelligence, sharing of genomic data insights, and obtaining certain advanced certifications. ProPhase and G42 Healthcare have also entered into an initial agreement with the goal of significantly synergizing the companies' genomic sequencing capabilities to support further development and globalization of their healthcare offerings. The areas of potential collaboration are intended to enable G42 Healthcare to acquire consumer-facing capabilities in providing patient-specific data, supporting gene therapy programs, and developing personalized medical treatment and therapies. "G42 Healthcare is an enabler of the world's largest and most comprehensive population genomics initiative - the Emirati Genome Program, which aims to move the traditional ecosystem from sick care to preventive healthcare for UAE's citizens, making G42 Healthcare an ideal strategic relationship for ProPhase as we look to bolster our next generation sequencing capabilities and build our new state-of-the-art genomic sequencing facility," commented Ted Karkus, ProPhase Lab's Chief Executive Officer. "The goal of these initiatives is to advance and diversify our genomic sequencing capabilities while improving operational efficiencies. We expect to realize cost savings through these objectives, which we will then pass on to our customers in an effort to accelerate sales growth."

08:21 EDT Kintara pauses REM-001 program in CMBC to conserve funds for VAL-083 - Kintara Therapeutics announced that the REM-001 program in Cutaneous Metastatic Breast Cancer was paused to conserve cash which will be used to support the funding of the company's ongoing international registrational study for VAL-083 in glioblastoma. By pausing the REM-001 program, the company expects to save approximately $3M through 2023. "Unfortunately, we decided to pause our REM-001 program at this time. CMBC patients and treating physicians have little or no treatment options for this underserved disease area. We will continue to explore ways to restart REM-001, including use of grants from applications currently under review to support the funding of the planned 15-patient CMBC study. Although this was a difficult decision, we believe saving approximately $3.0 million through calendar year 2023 is prudent given the current capital market conditions," stated Robert Hoffman, President and CEO of Kintara. "We continue to look forward to announcing top-line data for VAL-083 in GBM from the international registrational GBM AGILE study around the end of calendar year 2023."

08:20 EDT Stepstone Real Estate adds Uzmez as Managing Director of business development - StepStone Real Estate, the real estate arm of private markets investment firm StepStone, announced that Yasmine Uzmez has joined the firm as a Managing Director on its business development team. Uzmez will be based in StepStone's New York office. Uzmez has more than 18 years' experience in real estate and has held senior positions at real estate private placement firms Park Madison Partners and Shelter Rock Capital Advisors.

08:19 EDT Innoviva's subsidiary presents efficacy, safety data from Phase 3 ATTACK trial - Entasis Therapeutics, a wholly owned subsidiary of Innoviva, announced the presentation of additional safety and efficacy data from the Company's pivotal Phase 3 ATTACK trial. The study results will be presented at IDWeek 2022, the annual meeting of the Infectious Disease Society of America held October 19-23, 2022 in Washington, D.C. Oral Presentations: An oral presentation entitled Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex infections. Results of the study showed non-inferiority in 28-day all-cause mortality and overall trends favoring SUL-DUR, such as higher clinical cure rate at Test of Cure and greater microbiologic favorable response at Test of Cure. The study showed that treatment with SUL-DUR demonstrated lower mortality, higher clinical cure rates, and greater microbiologically favorable outcomes than colistin in patients with carbapenem-resistant ABC infections. The second oral presentation entitled Efficacy of sulbactam-durlobactam versus colistin in patients with extensively drug-resistant and pan-drug resistant Acinetobacter baumannii-calcoaceticus complex infections. Results showed that ABC isolates from patients in ATTACK were highly antibiotic-resistant, but greater than95% susceptible to SUL-DUR. Treatment with SUL-DUR demonstrated lower mortality, higher clinical cure rates, and greater microbiologically favorable outcomes than colistin in patients with XDR or PDR ABC infections. In global surveillance studies, 100% of PDR ABC isolates were susceptible to SUL-DUR. The third oral presentation titled Population pharmacokinetic, pharmacokinetic/pharmacodynamic attainment, and clinical pharmacokinetic/pharmacodynamic analyses for sulbactam-durlobactam to support dose selection for the treatment of Acinetobacter baumannii calcoaceticus complex infections. This study evaluated PPK in 373 subjects, including 110 patients who received SUL-DUR and underwent PK sampling in the pivotal Phase 3 ATTACK trial. Investigators concluded that simulated plasma and ELF exposures yielded greater than90% probability of target attainment, which when combined with the favorable efficacy and safety findings from ATTACK, support a dose of 1.0 g sulbactam/1.0 g durlobactam via a 3-hour infusion, every 6 hours in patients with normal renal function and renal function-based dose adjustments.

08:16 EDT VirTra announces VirTra Volumetric Video for realistic 3D humans - VirTra has introduced a breakthrough technology for the industry, "VirTra Volumetric Video", or "V3", which has the potential to provide a step-function change in training content. V3 combines the advantages of high-definition video and 3D characters coupled with the ability to affordably build a comprehensive library of training content suitable for screen-based or headset-based platforms to provide a novel, industry-first simulation training solution. "Exceptional training content is a key differentiator and compelling reason for so many customers to buy simulators from VirTra," said Bob Ferris, Chairman and Co-CEO of VirTra. "Our goal with this multi-year project was to propel simulation training content to new levels of effectiveness, whether on a screen or in a headset, and in the process, we have built the world's very best volumetric video capture studio. This is a tool needed to create characters and scenarios with unparalleled realism built for the three-dimensional world of headset-based training."

08:14 EDT Plug Power, Olin launch joint venture for 15-ton-per-day hydrogen plant - Plug Power (PLUG) and Olin Corporation (OLN) announced the launch of a joint venture to begin with the construction of a 15-ton-per-day hydrogen plant in St. Gabriel, Louisiana. The joint venture, named Hidrogenii, will support reliability of supply and speed to market for green hydrogen throughout North America, setting the foundation for broader collaboration between the two companies. Plug will be the exclusive marketer of the joint venture's hydrogen and provide logistical support for delivery, while Olin will provide reliable hydrogen supply and operational expertise. The plant will benefit from state and local tax subsidies. The construction of the plant will create 160 jobs in 2022 and 215 jobs in 2023. The plant is then expected to create more than 25 permanent full-time jobs in Louisiana.

08:12 EDT Galecto enters tinto collaboration agreement for phase 2 trial of GB1211 - Galecto announced that it has entered into a collaboration agreement for an investigator-initiated Phase 2 trial at Providence Portland Medical Center's Earle A. Chiles Research Institute, EACRI, to evaluate the safety and efficacy of GB1211, Galecto's first-in-class, oral small molecule galectin-3 inhibitor candidate, in combination with pembrolizumab. Galecto has committed to supply GB1211 for the Phase 2 trial. The randomized, double-blind placebo controlled, investigator-initiated Phase 2 trial will evaluate whether the addition of GB1211 increases the response rate of pembrolizumab in metastatic melanoma and HNSCC patients. The study will employ a fixed dose of GB1211 in conjunction with the standard therapeutic dose of pembrolizumab in patients with unresectable or metastatic melanoma or recurrent or metastatic HNSCC progressing during or after platinum-containing chemotherapy. In addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin-3 biology and checkpoint inhibition. The Phase 2 trial is expected to begin in 2023 and top line results of the combination are expected to be reported as early as 2025.

08:11 EDT Certara announces Japan's PMDA renewed licenses of its software - Certara announced that the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, has renewed its licenses of Certara's Simcyp Simulator, Phoenix biosimulation software, and Pinnacle 21 Enterprise software. "The adoption of biosimulation and technology to advance novel drug development continues to grow in Japan," said Certara's CEO William Feehery, Ph.D. "We are proud of our ongoing partnership with the PMDA and industry leaders in Japan, as we work together to drive the use of innovative approaches and deliver critical therapies to patients sooner."

08:10 EDT Univar adds four labs at its Solution Centers in Houston - Univar Solutions announced the addition of four pharmaceutical ingredient labs at its flagship Solution Centers in Houston, Texas; Osasco - Sao Paulo, Brazil; Mexico City, Mexico; and Essen, Germany. The new facilities, designed to foster innovation and growth for customers in life science markets, will provide technical services such as formulation and prototype development, performance and application testing, chemical and product performance analysis, and custom blending for various dosage forms including oral solid dose, or OSD, semi-solid, liquid, and topical.

08:09 EDT Air Liquide, Chevron, others team team on hydrogen project along US Gulf Coast - Air Liquide (AIQUY) , Chevron Corporation (CVX), LyondellBasell (LYB), and Unipe have announced their intent to collaborate on a joint study that will evaluate and potentially advance the development of a hydrogen and ammonia production facility along the U.S. Gulf Coast. The facility could support industrial decarbonization and mobility applications in the region and expand clean ammonia exports, helping to increase the supply of lower carbon power internationally. The potential project to be studied is intended to cover the end-to-end energy value chain, utilizing each participant's technical expertise in production, operational experience, storage, distribution, and export logistics. Collectively, the consortium will bring capabilities and expertise in air separation technology, hydrogen technologies, lower carbon intensity and renewable natural gas, carbon capture and storage CCS, electrolysis-based technologies, and petrochemicals. Specifically, the consortium will assess the potential for producing hydrogen using natural gas with CCS and renewable hydrogen via electrolysis to supply end-use markets, including the ammonia, petrochemicals, power, and mobility markets.

08:08 EDT Impact Biomedical partner GRDG to be featured in documentary - Daryl Thompson, founder of GRDG Sciences in Winter Haven, Florida, has spent a career working just out of the spotlight and inventing biological and medical technologies that, when fully deployed, could better the lives of people around the world. But all that may change as GRDG, a scientific research partner of Impact BioMedical, announced that it will be the subject of a documentary film highlighting the passion, the search, and the cutting-edge discoveries that push the company - and its founder - behind a single-minded goal: creating a healthier world quickly and naturally. The documentary project comes on the heels of GRDG's completion of Sombrero, a five-year multi-pronged project that yielded multiple patents and potentially billions of dollars in licensing opportunities.

08:07 EDT Equinix announces $45M investment in Colombia - Equinix announced a $45M investment in Colombia for the construction of BG2, a new International Business Exchange data center in Bogota, scheduled to open in the first half of 2023. With this new facility, Equinix is reinforcing its commitment to strengthening the digital economy across Latin America, with around 32,000 square feet of colocation space-expected to be one of the largest data centers in Colombia. BG2 will provide global and local businesses and partners alike with the ability to connect directly and securely to the world's digital economy, via comprehensive digital ecosystems.

08:06 EDT GSK announces interim results from ZOSTER-049 extension study of Shingrix - GSK plc announced "positive" interim results from the ZOSTER-049 extension study showing that overall Shingrix can provide at least a decade of protection against shingles after initial vaccination. The interim analysis data will be presented on October 20 at the IDWeek congress in Washington, DC. These results come from ZOSTER-049, an extension from two phase III clinical trials ZOE-50 and ZOE-70. From those trials, vaccine efficacy was 97% in adults 50 years and above and 91% in adults 70 years and above over a follow-up period of approximately four years. The ZOE-LTFU study, which follows participants from the ZOE-50 and ZOE-70 clinical trials for an additional six years, is ongoing and will continue to evaluate the longer-term efficacy, immunogenicity and safety of the vaccine. Sabine Luik, Chief Medical Officer & SVP Global Medical Regulatory & Quality, GSK, said: "We are delighted to see the continuing longevity of protection from our shingles vaccine. The findings from ZOE-LTFU demonstrate that it can provide a decade of protection against the pain, debilitating impact and potentially severe complications that shingles can cause in people aged 50 and over. These data significantly add to, and complement, the existing body of evidence demonstrating the long-term benefit of the vaccine, and we look forward to seeing additional results from this ongoing study."

08:02 EDT Axcelis announces shipments of Purion Power Series implanters - Axcelis Technologies announced multiple new and follow-on shipments of the Company's Purion Power Series implanters to leading power device chipmakers in both silicon and silicon carbide technologies. The systems include the Purion H200 high current, Purion H200 SiC high current, Purion XE SiC high energy, and the Purion M SiC medium current. These customers will use the systems in high volume production of power devices supporting automotive and other power management markets. President and CEO Mary Puma commented, "The power device market continues to drive our growth globally and will likely account for between 35 and 40% of our system shipments in 2022. This growth is a long-term trend driven by the transition to electric vehicles and should benefit Axcelis for many years to come."

07:49 EDT Ally Financial down 7.7% after Q3 earnings and revenue miss

07:47 EDT Marcus Theatres' loyalty program reaches 5M members - Marcus Theatres, a division of The Marcus Corporation , announces that its Magical Movie Rewards loyalty program has signed up its five millionth member. The milestone is a celebration of human reconnection as moviegoers continue to head back into theatres to experience the excitement of seeing movies on the big screen. Since its inception in 2014, the Magical Movie Rewards program has been a key to increasing customer loyalty and growing sales. Loyalty members receive one point for every dollar spent and earn a $5 reward for every 100 points accumulated. Members also benefit by having online ticketing fees waived, and receiving exclusive offers and personalized weekly emails. These perks, along with the overall moviegoing experience, drive attendance and repeat business. In fact loyalty members make up nearly half 46% of the overall attendance and on average visit the theatre four times per year. "The Magical Movie Rewards program is one of our strongest channels to learn about our moviegoers' expectations and preferences," said Mark Gramz, president of Marcus Theatres. "We provide what we believe will be of interest and value to our members, which creates a relationship and can lead to increased business. Welcoming our five millionth member confirms the continued interest in the program."

07:36 EDT Abbott 'particularly pleased' with sales growth rates in U.S. Medical Devices - "Our results and increased guidance in the current macroeconomic environment reflect the strength of our diversified business model and execution," said Robert Ford, chairman and CEO, Abbott. "We're particularly pleased with improving sales growth rates in U.S. Medical Devices, which is being fueled by several recent product launches, as well as continued strong performance in Established Pharmaceuticals."

07:33 EDT FTI's Technology segment expands legal department transformation solutions - FTI Consulting announced that the firm's Technology segment has further expanded its legal department transformation solutions from the Corporate Legal Operations practice. Tackling an enhanced list of top focus areas for corporate legal departments - including business strategy alignment, legal technology adoption, processes and spend management - the team can deliver assessments with actionable roadmaps for program improvement, alongside comprehensive services and technology that support the entirety of legal operations transformation.

07:30 EDT Ally Financial sees uncertainty ahead - "While we remain focused on delivering solid results each quarter, we're actively monitoring the uncertainty which lies ahead", said CEO, Jeffrey J. Brown. "The specific path the economy will take over the next few quarters is unclear, but Ally has an incredibly strong foundation in our people and businesses. Our 'Do It Right' culture underpins everything we do. We've fostered an owners' mentality across more than 11,000 teammates which heightens our focus on risk management and unwavering focus on controlling what we can control. Our teams have demonstrated an ability to deliver results across a variety of operating environments and we will leverage that expertise in executing against our strategic priorities. We're focused on continuing to be the leading digital financial services company and delivering long-term value for all our stakeholders."

07:20 EDT Ondas' American Robotics receives purchase order from oil, gas company - Ondas Holdings announced that American Robotics has received a new purchase order from a leading U.S. oil and gas company. Adding another high-level company to its customer base, American Robotics' autonomous drone technology continues to provide the nation's leading oil and gas companies with the technology needed to streamline monitoring and inspections.

07:17 EDT Auddia announces uer performance metrics, announces new features for faidr - Auddia announced "positive" user data with costs-per-install, CPI, through Q3 continuing to decline as the Company gains visibility to reaching a CPI below $2 as user adoption and organic customer referrals increase. Auddia is continuing to execute on the process of optimizing the user experience, improving performance metrics, and quantifying subscription conversion rates in preparation for providing 2023 revenue guidance with Q3 filings in mid-November. The Company is currently conducting its second test of subscription conversion rates after the first test saw an 8.5% subscription conversion rate, exceeding internal expectations of 5%. Auddia is hoping to exceed 8.5% with the most recent test, which concludes on November 9, 2022. "faidr's audience prefers choosing what they want to hear on AM/FM radio streams. The app launched in February and, according to AppsFlyer data, faidr is already performing in the top 10% of music and entertainment apps for retention," said Michael Lawless, Auddia's CEO. "This is particularly encouraging given that mobile app strategies to optimize retention have not yet been implemented. As those strategies are integrated into our marketing efforts, we expect retention to have a meaningful uptick. By adding podcasts and faidrRadio content, we're empowering listeners with more choices while supporting our partners and independent music creators. We expect these content strategies to also have a significant impact on retention improvement."

07:15 EDT Kamada awarded $22M extension of Canadian supply tender - Kamada announced that the Company was awarded an extension of an existing tender from the Canadian Blood Services, CBS, for the supply of four IgG products, CYTOGAM, HEPAGAM, VARIZIG and WINRHO SDF, for an additional three years for an approximate total value of $22M. This award secures the ongoing sales of those products in the Canadian market. The four commercial products, approved by Health Canada and the U.S. Food and Drug Administration, were acquired by Kamada in November 2021. CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec. The extension with CBS is for a three-year period, commencing on April 1, 2023, with an option to extend for up to two additional years. "This award, together with KAMRAB as the primary anti-Rabies IgG product used in Canada, validates our position as the leading specialty IgG company in that important geography," said Amir London, Kamada's Chief Executive Officer. "This achievement represents the second significant tender we have recently secured, following the new $11.4 million supply agreement won for VARIZIG from an international organization operating principally in Latin America. We remain confident that significant commercial potential exists for our IgG portfolio in international markets and intend to continue pursuing additional contracts in key strategic territories.

07:13 EDT Breckenridge Distillery announces collaboration with Breckenridge Brewery - Breckenridge Distillery, a subsidiary of Tilray Brands, and Breckenridge Brewery return this season for the second ever Buddy Pass, a barrel-exchange program to create a limited-edition Imperial Stout Cask Finish Whiskey and a Whiskey Barrel-Aged Imperial Oatmeal Stout Beer. Buddy Pass has expanded nationwide, entering 10 new markets and will hit retailers starting Oct. 24. The collaboration begins with Breckenridge Brewery's Imperial Oatmeal Stout beer aged in Breckenridge Distillery Bourbon barrels. After the beer is sufficiently aged, the barrels are returned to Breckenridge Distillery where they are filled once again with the distillery's whiskey.

07:10 EDT Nuwellis appoints Blake as Chief Financial Officer - Nuwellis announced the appointment of Lynn Blake as Chief Financial Officer, effective October 19, 2022. Blake brings more than two decades of senior financial leadership experience. Most recently, she served as a Managing Director at Growth Operators Advisory Services.

07:09 EDT Equinox Gold announces results of Feasibility Study to expand Los Filos Mine - Equinox Gold announced the results of a Feasibility Study for an expansion at the Company's 100%-owned Los Filos Mine Complex located in Mexico. Current Los Filos operations consist of both run-of-mine, or ROM, and crushed ore heap leach facilities. With continued development of the Bermejal Underground deposit and construction of a 10,000 tonnes per day, or t/d, carbon-in-leach, or CIL, processing plant, the Los Filos mine life would be extended to 14.5 years with life-of-mine, or LOM, average annual production increasing to 280,000 ounces of gold at all-in sustaining costs, or AISC, of $1,081 per oz. Total LOM production is estimated at 3.97 million oz of gold. Peak production during 2025-2030 averages 360,000 oz of gold per year. Using the base case $1,675/oz gold price, the expansion project has an after-tax net present value discounted at 5% of $625M with an internal rate of return, or IRR of 26%. Gold mineralization at Los Filos extends beyond the drilled area, and it is expected that additional drilling along the contact between intrusive and carbonate rock could identify further skarn mineralization. With exploration success and conversion of Mineral Resources to Mineral Reserves, considerable potential exists to extend the Los Filos mine life beyond 2036.

07:08 EDT Acorda says three proxy advisory firms advise reverse stock split - Acorda Therapeutics announced that the three leading, independent proxy advisory firms - Institutional Shareholder Services, Glass Lewis and Co and Egan-Jones all recommend that shareholders vote "For" Proposal 2, Reverse Stock Split, at Acorda's Special Meeting of Stockholders, scheduled for November 4. "We appreciate the confirmation of the need for and urgency of this proposal," said John P. Kelley, Chair of Acorda's Board of Directors. "The proposal to allow the board to implement a reverse split, if necessary, is critical to ensure that Acorda does not become delisted from Nasdaq. If delisting were to occur, we may be in default on our agreements with our debtholders, and may need to declare bankruptcy." Stockholders are encouraged to cast your vote promptly FOR the Reverse Split proposal without further delay.

07:07 EDT Nasdaq sees 2022 non-GAAP tax rate 24%-25% - The company is narrowing its 2022 non-GAAP operating expense guidance to a range of $1,700 to $1,720 million. Nasdaq expects its 2022 non-GAAP tax rate to be in the range of 24% to 25%.

07:07 EDT Cheniere Energy joins Oil and Gas Methane Partnership 2.0 - Cheniere Energy announced that it has joined the Oil and Gas Methane Partnership, or OGMP, 2.0, the United Nations Environment Program's, or UNEP, flagship oil and gas methane emissions reporting and mitigation initiative. OGMP 2.0 is a measurement-based reporting framework intended to improve the accuracy and transparency of methane emissions reporting in the oil and gas sector. Cheniere joins OGMP 2.0 as part of the company's continued commitment to increased climate transparency and data-driven actions that address methane emissions.

07:06 EDT Healthcare Services increases quarterly dividend to 21.5c per share - The company's board of directors declared a quarterly cash dividend of 21.5c per common share, payable on December 22 to shareholders of record at the close of business on November 18. This represents the 78th consecutive quarterly cash dividend payment, as well as the 77th consecutive increase since the initiation of quarterly cash dividend payments in 2003.

07:02 EDT RedHill granted of further method that protects administration of opaganib - RedHill Biopharma announced the granting by the United States Patent and Trademark Office, or USPTO, of a further method of use patent that protects the administration of opaganib for the inhibition of a disease caused by a coronavirus in a subgroup population of patients requiring a fraction of inspired oxygen, or FiO2, up to and including 60% at baseline, adding to the existing strong patent suite covering opaganib. The new patent, expiring in 2041, titled "Sphingosine Kinase 2 Inhibitor for Treating Coronavirus Infection in Moderately Severe Patients with Pneumonia", protects the results from a post-hoc analysis from the global Phase 2/3 study in hospitalized patients with COVID-19 pneumonia (NCT04467840). This analysis of 251 study participants requiring a FiO2 up to and including 60% at baseline demonstrated that treatment with oral opaganib resulted in a 62% reduction in mortality, improved outcomes in time to room air and median time to hospital discharge, and a reduced likelihood of intubation and mechanical ventilation in this large group of hospitalized, moderately severe COVID-19 patients.Late-stage development of opaganib is ongoing pending Phase 3 trial design regulatory approvals and securing of external funding.

07:01 EDT Stepan Company increases quarterly dividend to 36.5c per share - Stepan Company reported that its board of directors approved an increase of 3c per share, or 9%, on its quarterly cash dividend on its common stock. The dividend of 36.5c per share is payable on December 15 to common stockholders of record on November 30. The increase marks the 55th consecutive year in which the quarterly dividend rate on the company's common stock has increased.

06:58 EDT Procter & Gamble CEO says 'very difficult cost and operating environment' - "We delivered solid results in our first quarter of fiscal 2023 in a very difficult cost and operating environment," said Jon Moeller, Chairman of the Board, President and CEO. "These results enable us to maintain our guidance ranges for organic sales and EPS growth for the fiscal year despite continued significant headwinds. We remain committed to our integrated strategies of a focused product portfolio, superiority, productivity, constructive disruption and an agile and accountable organization structure. These strategies have enabled us to build and sustain strong momentum. They remain the right strategies to navigate through the near-term challenges we're facing and continue to deliver balanced growth and value creation."

06:46 EDT KalVista announces publication of new sebetralstat data in two journals - KalVista Pharmaceuticals announced the publication of new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica. The Journal of Medicinal Chemistry article focuses on the medicinal chemistry KalVista conducted that led to the discovery of sebetralstat, with properties optimized for the on-demand treatment of hereditary angioedema, or HAE. Data with sebetralstat showed high selectivity against related human serine proteases. This feature, together with the rapid and high plasma exposure and near-complete inhibition of plasma kallikrein, or PKa, in preclinical studies, supported its progression into toxicology and ultimately clinical assessment. Sebetralstat has since advanced to phase 3 trials. In Xenobiotica, sebetralstat was shown to be rapidly absorbed into the systemic circulation and demonstrated absorption, metabolism, and excretion properties that would be beneficial for on-demand treatment of HAE attacks.

06:33 EDT Ayala Pharmaceuticals, Advaxis enter merger agreement - Ayala Pharmaceuticals (AYLA) and Advaxis (ADXS) announced that they have entered into a definitive merger agreement. The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala's lead program AL102 for the treatment of desmoid tumors and Advaxis's candidate ADXS-504 in development for prostate cancer. Subject to the terms and conditions of the merger agreement, at the closing of the merger, each outstanding share of Ayala common stock will be converted into the right to receive shares of common stock of Advaxis based on the exchange ratio set forth in the merger agreement. Upon completion of the merger, Ayala stockholders will own approximately 62.5% of the combined company's outstanding common stock and Advaxis stockholders will own approximately 37.5%, subject to the terms of the merger agreement. Advaxis will, at the effective time of the merger, assume the outstanding restricted stock units and stock options of Ayala, subject to the terms of the merger agreement. No fractional shares will be issued in connection with the merger and Advaxis will pay cash in lieu of any such fractional shares. The merger is intended to qualify for U.S. federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended. Consummation of the merger is subject to certain closing conditions, including, among other things, approval by the stockholders of Ayala. At the closing of the merger, Ayala will be delisted from The Nasdaq Global Market. The combined company's common stock is expected to begin trading on the OTCQX at the effective time of the merger, subject to Advaxis' planned efforts to have the stock of the combined company listed on Nasdaq, as to which no assurances can be made.

06:31 EDT Ayala Pharmaceuticals, Advaxis enter merger agreement

06:10 EDT Zymeworks, Jazz Pharmaceuticals enter licensing agreement for zanidatamab - Zymeworks (ZYME) announced that management will host a conference call and webcast to discuss Zymeworks has entered into an exclusive licensing agreement for zanidatamab, a HER2-targeted bispecific antibody developed using Zymeworks' proprietary Azymetric platform, with Jazz Pharmaceuticals (JAZZ). Zymeworks to receive $50M upfront payment, a second payment of $325M, at Jazz's option, and further potential regulatory and commercial milestones for total potential payments of up to $1.76B.

06:08 EDT BioVie reports full enrollment in Phase 2 trial of NE3107 - BioVie announced that the company's Phase 2 trial assessing NE3107's potential pro-motoric impact in Parkinson's disease has fully enrolled 44 patients. Topline data readout is expected in December.

06:05 EDT Jazz Pharmaceuticals, Zymeworks announce zanidatamab exclusive license agreement - Jazz Pharmaceuticals (JAZZ) and Zymeworks (ZYME) announced that Jazz and Zymeworks' subsidiary, Zymeworks BC, have entered into an exclusive licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks' zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks. Zanidatamab, a HER2-targeted bispecific antibody with novel mechanisms of action, has demonstrated anti-tumor activity in several HER2-expressing cancers, both as monotherapy and in combination with chemotherapy and other agents. Zanidatamab is currently in pivotal trials as a second-line treatment for HER2-expressing biliary tract cancer, or BTC, and as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, or GEA. In BTC, where no HER2-targeted therapies are currently approved, the FDA has granted Breakthrough Therapy designation for zanidatamab, positioning it as a potential first-in-class therapy. Under the terms of the agreement, Jazz will receive an exclusive license to develop and commercialize zanidatamab in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene (BGNE). Zymeworks is eligible to receive a $50M upfront payment, following receipt of the clearance relating to the United States Hart-Scott Rodino Antitrust Improvements Act of 1976 and should Jazz decide to continue the collaboration following readout of the top-line clinical data from HERIZON-BTC-01, a second, one-time payment of $325M. Zymeworks is also eligible to receive up to $525M upon the achievement of certain regulatory milestones and up to $862.5M in potential commercial milestone payments, for total potential payments of up to $1.76B. Pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz's net sales. Closing of the agreement is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Act of 1976. The transaction is expected to close within the 2022 calendar year. Zymeworks management will host a conference call and webcast for investors and analysts on October 19 at 8:00 a.m. ET.

06:02 EDT Elevance Health reports Medical enrollment of 47.3M members - Medical enrollment increased 2.2M members year-over-year and 232,000 members during the quarter to 47.3M. members.

05:35 EDT Spirit AeroSystems enters MOU with Joramco for MRO services cooperation - Spirit AeroSystems announced at MRO Europe in London a memorandum of understanding, or MOU, with Joramco, the Amman-based maintenance, repair, and overhaul, or MRO, provider and the engineering arm of Dubai Aerospace Enterprise, or DAE, to explore cooperation in providing a wide range of repairs to and services of composite and metallic aerostructures to customers in the region. A team of engineers and experts from both companies will be formed to support the needs of operators, and shops, and develop new repair processes as needed. Joramco, based at Queen Alia International Airport in Amman, Jordan, has more than 50 years of experience. It has built a solid track record as a leading independent commercial aircraft maintenance, repair and overhaul facility serving a wide range of customers in the Middle East, Europe, South Asia, and Africa, offering services on several aircraft models. Joramco is certified by many international regulatory authorities including the European Aviation Safety Agency, the U.S. Federal Aviation Administration and the Jordanian Civil Aviation Regulatory Commission.

05:31 EDT Box renews partnership with Japan's Ministry of the Environment - Box announced a renewed partnership with Japan's Ministry of the Environment. With Box, the Ministry of the Environment will digitize and streamline administrative operations contributing to improved productivity and better public services by transforming the work styles of employees. The Ministry of the Environment will also benefit from Box's advanced security features.

05:22 EDT Vaalco Energy reports Q3 production 9,150 net BOPD, completes Etame FSO - Vaalco Energy announced the completion of the Floating Storage and Offloading vessel, or FSO, installation and field reconfiguration at Etame. Additionally, the company disclosed strong Q3 production which was above the high-end of quarterly guidance and sales volumes that were above the midpoint of quarterly guidance. Additionally, the company reported Vaalco standalone third quarter production and sales volumes both above the midpoint of our guidance ranges. Production for the third quarter was approximately 9,150 net BOPD and sales volumes were approximately 7,952 net BOPD. The company was able to complete three liftings during the quarter plus an additional smaller one on October 5, shortly before the FPSO was decommissioned. The team overlapped the maintenance turnaround with the field reconfiguration to minimize downtime and deliver operating efficiencies. Since the strategic combination with TransGlobe Energy did not close until October 14 production volumes and associated revenues and expenses will not be included in Vaalco's financial results until post-closing in the fourth quarter of 2022. However, the company said that the majority of the transaction costs associated with the strategic combination were incurred in the third quarter and will be recognized as special, one-time expenses in third quarter financial results. The company also expects to incur a realized derivative loss in the third quarter as a result of the settlement of the remaining derivative swaps. Both the transaction costs and realized derivative losses are not deductible for Gabonese taxes, so the effective tax rate will be higher than normal during the third quarter. Additionally, costs associated with the relinquishment of the FPSO and transition to the FSO will be included in the third quarter.

05:13 EDT Paysafe announces new integrated payments partnership with HotelKey - Paysafe announced a new integrated payments partnership with HotelKey, a cloud-based software solution provider for the hospitality industry. Paysafe will integrate with HotelKey's software solutions to streamline payments for U.S. hotels across their front-desk, hospitality, retail, food and beverage, and other back-of-house operations. HotelKey's software solutions are currently deployed across thousands of hotels in the U.S. and are designed to help individual properties and hotel chains, including independently-owned and franchised hotels, manage their end-to-end guest operations. Paysafe will support HotelKey's mission to simplify hotel property management by establishing a centralized hub for payment processing to securely process in-person, card-present and card-not-present transactions across all designated sales channels.